Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.

The intestinal efflux pump, P-glycoprotein (P-gp), located in the apical membranes of intestinal absorptive cells, can reduce the bioavailability of a wide range of drugs which are substrates for this membrane transporter. In addition to anticancer and anti-HIV drugs, NCEs for other disease indications are P-gp substrates and there is considerable interest in inhibiting P-gp and thus increasing the bioavailability of these molecules. In this review article, an overview of P-gp and its role in drug transport and absorption will be presented first and then formulation strategies to effectively inhibit P-gp will be discussed and compared. These strategies independently and in combination, are: (a) coadministration of another P-gp substrate/specific inhibitor, and (b) incorporation of a nonspecific lipid and/or polymer excipient in the formulation. The first approach, although very effective in inhibiting P-gp, utilizes a second active compound in the formulation and thus imposes regulatory constraints and long development timelines on such combination products. Excipient inhibitors appear to have minimal nonspecific pharmacological activity and thus potential side effects of specific active compound inhibitors can be avoided. Case studies will be presented where specific active compounds, surfactants, polymers, and formulations incorporating these molecules are shown to significantly improve the intestinal absorption of poorly soluble and absorbed drugs as a result of P-gp inhibition and enhanced drug transport in vitro.

[1]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[2]  Lawrence X. Yu,et al.  Effect of common excipients on Caco-2 transport of low-permeability drugs. , 2001, Journal of pharmaceutical sciences.

[3]  S. Benita,et al.  Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  J. Silverman,et al.  Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) , 1999, Pharmaceutical Research.

[5]  L. Benet,et al.  The effect of water‐soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers , 1996, Clinical pharmacology and therapeutics.

[6]  Michael Boyd,et al.  Effects of Lipid-Based Oral Formulations on Plasma and Tissue Amphotericin B Concentrations and Renal Toxicity in Male Rats , 2003, Antimicrobial Agents and Chemotherapy.

[7]  Lawrence X. Yu,et al.  Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 , 1999, Pharmaceutical Research.

[8]  F. Sinicrope,et al.  Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. , 1992, The Journal of biological chemistry.

[9]  H. Burt,et al.  Evidence for Modulation of P-glycoprotein-Mediated Efflux by Methoxypolyethylene Glycol-block-Polycaprolactone Amphiphilic Diblock Copolymers , 2004, Pharmaceutical Research.

[10]  C. Dey,et al.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. , 2003, Pharmacological research.

[11]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[12]  R. Sokol,et al.  Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E , 1991, The Lancet.

[13]  Ronald T Borchardt,et al.  A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. , 2002, Journal of pharmaceutical sciences.

[14]  Michael Boyd,et al.  Potential Mechanisms by Which Peceol® Increases the Gastrointestinal Absorption of Amphotericin B , 2004, Drug development and industrial pharmacy.

[15]  S. Mizrahi,et al.  Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. , 1993, Transplantation proceedings.

[16]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Jochem Alsenz,et al.  The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. , 2003, Journal of pharmaceutical sciences.

[18]  J. Alsenz,et al.  Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.

[19]  M. Wempe,et al.  Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Christopher J. H. Porter,et al.  An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine , 2002, AAPS PharmSci.

[21]  T. Amachi,et al.  Recent progress in P-glycoprotein research. , 1999, Anti-cancer drug design.

[22]  F. Loor,et al.  Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. , 1996, Anti-cancer drugs.

[23]  F. Sharom,et al.  The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. , 1999, Biochemistry.

[24]  P. Constantinides,et al.  Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects , 1995, Pharmaceutical Research.

[25]  B. Hirst,et al.  Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption , 1997 .

[26]  M. Borgnia,et al.  Competition of Hydrophobic Peptides, Cytotoxic Drugs, and Chemosensitizers on a Common P-glycoprotein Pharmacophore as Revealed by Its ATPase Activity (*) , 1996, The Journal of Biological Chemistry.

[27]  Y. Lo,et al.  Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. , 2000, Biochemical pharmacology.

[28]  Colin W. Pouton,et al.  Formulation of self-emulsifying drug delivery systems , 1997 .

[29]  J. Coon,et al.  Comparison of solutol HS 15, cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents , 1995, International journal of cancer.

[30]  C. Rocha,et al.  Pre-clinical and clinical evaluation of solution and soft gelatin capsule formulations for a BCS class 3 compound with atypical physicochemical properties. , 2004, Journal of pharmaceutical sciences.

[31]  Sung-Joo Hwang,et al.  Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031 , 2004, Pharmaceutical Research.

[32]  W. Rubas,et al.  An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro , 2004, Pharmaceutical Research.

[33]  D. D. de Alwis,et al.  Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. , 2003, Advanced drug delivery reviews.

[34]  Peter Höglund,et al.  Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  Y. Lo,et al.  Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[36]  T. Horie,et al.  Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx. , 2000, Cancer letters.

[37]  A. Seelig,et al.  Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[38]  J. Beijnen,et al.  Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. , 1997, British Journal of Cancer.

[39]  P. Gao,et al.  Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. , 2003, Journal of pharmaceutical sciences.

[40]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[41]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. , 1992, Journal of pharmaceutical sciences.

[42]  S. Davis,et al.  Advances in the Use of Tocols as Drug Delivery Vehicles , 2006, Pharmaceutical Research.

[43]  M. Varma,et al.  Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  S. Benita,et al.  Enhanced Oral Absorption of Paclitaxel in a Novel Self-Microemulsifying Drug Delivery System with or Without Concomitant Use of P-Glycoprotein Inhibitors , 2004, Pharmaceutical Research.

[45]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  J. Schellens,et al.  Oral Delivery of Taxanes , 2001, Investigational New Drugs.

[47]  Y. Assaraf,et al.  Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. , 1999, European journal of biochemistry.

[48]  M. Gottesman,et al.  Is the multidrug transporter a flippase? , 1992, Trends in biochemical sciences.

[49]  Alan R. Boobis,et al.  In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report , 2001, European Journal of Clinical Pharmacology.

[50]  Georges Houin,et al.  Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. , 2004, International journal of pharmaceutics.

[51]  Y. Assaraf,et al.  The Role of Passive Transbilayer Drug Movement in Multidrug Resistance and Its Modulation* , 1996, The Journal of Biological Chemistry.

[52]  J. Schellens,et al.  Modulation of oral bioavailability of anticancer drugs: from mouse to man. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[53]  P. Rosenthal,et al.  Enhanced Oral Cyclosporine Absorption With Water‐Soluble Vitamin E Early After Liver Transplantation , 1996, Pharmacotherapy.